Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 1/20 | 0.54 |
| ▸ | TDP2 | O95551 | 1/20 | 0.54 |
| ▸ | DHODH | Q02127 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | CDC25B | P30305 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CDC25A | P30304 | 1/20 | 0.50 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.50 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8942748 | 0.86 | CASP3 (0.48) | APAF1TDP2DHODHKMT2AMAPT | |
| SCHEMBL31492702 | 0.82 | APAF1 (0.50) | APAF1TDP2DHODHKMT2AMAPT | |
| SCHEMBL5821364 | 0.82 | APAF1 (0.65) | APAF1TDP2DHODHKMT2AMAPT | |
| SCHEMBL12127298 | 0.79 | DHODH (0.79) | APAF1TDP2DHODHKMT2AMAPT | |
| SCHEMBL14765285 | 0.79 | APAF1 (0.50) | APAF1TDP2DHODHKMT2AMAPT | |
| SCHEMBL6052720 | 0.79 | MAPT (0.51) | APAF1TDP2DHODHKMT2AMAPT | |
| Lapachol SCHEMBL157255 | 0.79 | DHODH (0.79) | APAF1TDP2DHODHKMT2AMAPT | |
| Lapachol SCHEMBL31492698 | 0.79 | DHODH (0.79) | APAF1TDP2DHODHKMT2AMAPT | |
| SCHEMBL9444192 | 0.78 | APAF1 (0.46) | APAF1TDP2DHODHKMT2AMAPT | |
| SCHEMBL1520566 | 0.78 | APAF1 (0.65) | APAF1TDP2DHODHKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10076471-B2 | Antimicrobial denture | UNIVERSITY OF DAMMAM (SA) | 2018-09-18 | — | — | US | claimed |
| US-20170367934-A1 | ANTIMICROBIAL DENTURE | UNIVERSITY OF DAMMAM (SA) | 2017-12-28 | — | — | US | claimed |
| US-20090324682-A1 | Medical stent provided with inhibitors of atp synthesis | INTERSTITIAL THERAPEUTICS (CH) | 2009-12-31 | — | — | US | claimed |
| EP-1789029-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | Interstitial Therapeutics (CH) | 2007-05-30 | — | — | EP | claimed |
| EP-1789107-A2 | MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | Interstitial Therapeutics (CH) | 2007-05-30 | — | — | EP | claimed |
| WO-2006024489-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2006024488-A2 | MEDICAL STENT PROVIDED WITH INHIBITORS OF ATP SYNTHESIS | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| WO-2006024491-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CELL PROLIFERATION | INTERSTITIAL THERAPEUTICS (CH) | 2006-03-09 | — | — | WO | claimed |
| US-5225578-A | 2-(1-alkylaminoalkyl)-3-hydroxy-1,4-naphthoquinone, process for its production and processes for producing 2-(1-alkenyl)-3-hydroxy-1,4-naphthoquinone and 2-alkyl-3-acyloxy-1,4-naphthoquinone by using it | KAWASAKI KASEI CHEMICALS LTD. (JP) | 1993-07-06 | — | — | US | claimed |
| EP-0330186-B1 | 2-(1-ALKYLAMINOALKYL)-3-HYDROXY-1,4-NAPHTHOQUINONE, PROCESS FOR ITS PRODUCTION AND PROCESSES FOR PRODUCING 2-(1-ALKENYL)-3-HYDROXY-1,4-NAPHTHOQUINONE AND 2-ALKYL-3-ACYLOXY-1,4-NAPHTHOQUINONE BY USING IT | KAWASAKI KASEI CHEMICALS LTD. (JP) | 1993-05-19 | — | — | EP | claimed |
| EP-0330186-A2 | 2-(1-alkylaminoalkyl)-3-hydroxy-1,4-naphthoquinone, process for its production and processes for producing 2-(1-alkenyl)-3-hydroxy-1,4-naphthoquinone and 2-alkyl-3-acyloxy-1,4-naphthoquinone by using it | KAWASAKI KASEI CHEMICALS LTD. (JP) | 1989-08-30 | — | — | EP | claimed |
| JP-1287058-A | — | — | None | — | — | JP | disclosed |
| JP-1216952-A | — | — | None | — | — | JP | disclosed |
| US-20240041702-A1 | METHOD OF REDUCING BACTERIAL ACTIVITY IN THE ORAL CAVITY OF A PATIENT | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2024-02-08 | — | — | US | disclosed |
| US-11839664-B1 | Denture having polished cameo surface and unpolished intaglio surface | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-12-12 | — | — | US | disclosed |
| US-4082848-A | MITICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1978-04-04 | — | — | US | disclosed |
| US-4070481-A | Substituted 2-higher alkyl-3-hydroxy-1,4-naphthoquinone carboxylic acid esters and their use as miticides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1978-01-24 | — | — | US | disclosed |
| US-4055661-A | Miticidal and aphicidal method utilizing 2-higher alkyl-3-hydroxy-1,4-naphthoquinone carboxylic acid esters | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-10-25 | — | — | US | disclosed |
| US-4053634-A | MITICIDAL AND APHICIDAL METHOD UTILIZING 2-HIGHER ALKYL-3-HYDROXY-1,4-NAPHTHOQUINONE CARBOXYLIC ACID ESTERS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-10-11 | — | — | US | disclosed |
| US-3948920-A | New anti-malarial agents | AKTIEBOLAGET ASTRA (SW) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324682-A1 | Medical stent provided with inhibitors of atp synthesis | ATP5ME, ATP5F1A, ATP5MG | APAF1 3098/4885TDP2 4149/4885DHODH 487/4885 |
| US-10076471-B2 | Antimicrobial denture | TAS2R50, TAS2R60, TAS2R20 | APAF1 3716/4885TDP2 3996/4885DHODH 685/4885 |
| US-20170367934-A1 | ANTIMICROBIAL DENTURE | TAS2R50, TAS2R60, TAS2R20 | APAF1 3716/4885TDP2 3996/4885DHODH 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.